CNS Pharmaceuticals CNSP shares are trading higher on Monday.
The company announced that independent research from the University of Frankfurt showed that an active compound in WP1122 completely prevented coronavirus replication in vitro.
CNS Pharmaceuticals is a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors.
CNS Pharmaceuticals shares were trading up 9.28% at $3.65 on Monday. The stock has a 52-week high of $5.69 and a 52-week low of $1.26.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
